Neuroscience

Agreement covers worldwide rights for the development, commercialization of Concert’s deuterium-modified sodium oxybate (D-SXB) compounds

Bolstering scientists’ understanding of the epigenetic underpinnings of depression, a team of researchers from the Icahn School of Medicine at Mount Sinai have identified the epigenetic regulation of a protein called Rac1, which induces synaptic remodeling in stress disorders and depression

Companies to co-promote products in Japan

Fair deserves a rest. A more precise set of words could include meritorious, disciplined and ethical.

Transaction gains the company an inhaled migraine treatment and compounds for Parkinson’s, epilepsy

Drug candidates to target M4 receptor as potential treatments for neuropsychiatric symptoms of Alzheimer 's, schizophrenia

Sarepta Therapeutics announced last month a collaboration with University College London for the development of an exon-skipping drug targeting exon 53, its fourth drug in development, in support of Sarepta’s broad-based program for the treatment of Duchenne muscular dystrophy (DMD)

Cognitive abilities and psychiatric diseases unique to humans could be based on genomic features distinguishing our brain cells, including neurons, from those of other primates, according to a new study by researchers from the departments of Psychiatry and Neuroscience at the Mount Sinai School of Medicine

Autism Speaks grants $2 million to DELSIA to fund the partnership

Research targets the neurotransmitter glutamate

Janssen-funded public-private partnership compares Down Syndrome to Alzheimer’s disease

EGFR inhibitors demonstrate ability to reverse memory loss in fruit flies and animal models of Alzheimer's